Drug Target Review – Issue 1 2023
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
List view / Grid view
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
Tune into this podcast to hear experts discuss imaging and analysing data from organoids!
In this article Drug Target Review's Izzy Wood highlights three of the latest findings using lab automation techniques and technologies that aid scientists.
The resulting compounds, which can bind to spike proteins from the original coronavirus, could serve as a starting point for developing broad-spectrum treatments for COVID-19.
Technology is infamous for falling into a hype cycle, with its peaks and valleys of exaggerated expectations and disillusionment — AI-driven drug discovery is no exception. In this article, Aaron Daugherty, Vice President Discovery at Aria Pharmaceuticals, highlights how the industry can use AI to transform research.
US researchers use new imaging technique to see cardiac reactions to noradrenaline, the ‘fight or flight’ hormone.
A novel all-optical system uses optogenetics, machine vision cameras, and off-the-shelf components to stimulate and image engineered networks of human heart cells.
Swedish researchers unveiled a new cancer protein profile database compiled from artificial intelligence and machine learning.
In this ebook are articles on how artificial intelligence can be used to identify drug candidates, data-lead screening models and autonomous strategies for molecular discovery.
A study has proposed a new technique for modelling living cells at atomic resolution, which could be used to research human health.
A geometric deep-learning model is faster and more accurate than state-of-the-art computational models, reducing the chances and costs of drug trial failures.
Jiankun Lyu hopes to use algorithms to find improved drugs by screening chemicals that may look different to a protein’s known ligands but work in a similar way.
Using an AI algorithm that models drug and target protein interactions, researchers achieved up to 97 percent accuracy in identifying promising drug candidates.
The researchers created a chronic skull optical clearing window where they no longer needed to remove any piece of the skull.
Scientists have identified and synthesised a small molecule that could be a more accessible and affective alternative to an antibody that treats a wide range of cancers.